The NPA has already submitted several statements in different modules of the Covid-19 Inquiry, highlighting the vital role pharmacies played during the emergency
Jonathan Rees, a member of the National Pharmacy Association (NPA), will become the first pharmacist to present oral evidence at the UK Covid-19 Inquiry hearings tomorrow (Thursday, 10 October).
During the pandemic, Jonathan worked at Penclawdd Pharmacy near Swansea, while also supporting the NPA’s efforts to respond to the extra needs of its members across Wales during the peak of the crisis.
Jonathan is expected to give evidence about the role and responsibilities of pharmacies during the pandemic, the impact of the pandemic on pharmacy services, working conditions and medicines supply, and the challenges faced in obtaining Personal Protective Equipment Equipment (PPE).
Commenting on the significance of this milestone, NPA chief executive Paul Rees stated: “The NPA is proud to be telling the story of the vital role pharmacies played during the Covid pandemic, and ensuring that our members’ voices are heard in this inquiry.
“We’re determined that lessons will be learned about the importance of properly funding this vital public health network – in readiness for future crises - and that tomorrow’s history books will record the heroics of pharmacy teams across the UK.
“We’re certain that Jonathan’s testimony will exemplify the high level of care, responsiveness and commitment to duty demonstrated by pharmacies in Wales and across the UK during the pandemic.”
The NPA is the only community pharmacy employer body to be recognised as a core participant in the inquiry, allowing it to put on record the vital role of community pharmacies during a time of national emergency.
The association has already submitted several statements in different modules of the inquiry.
It reiterated its commitment to advocating for the priorities of community pharmacy throughout the proceedings.
Other NPA witnesses may be called to provide evidence in the future, the association said.
